EMFAT
IMDX

Emerald Mutual Fund Advisers Trust’s Insight Molecular Diagnostics IMDX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-101,795
Closed -$4.99M – 326
2020
Q1 		$4.99M Hold
101,795
– – 0.31% 101
2019
Q4 		$4.58M Sell
101,795
-19,714
-16% -$711K 0.19% 139
2019
Q3 		$5.1M Buy
121,509
+2,500
+2% +$98.3K 0.23% 126
2019
Q2 		$5.93M Sell
119,009
-5,491
-4% -$456K 0.24% 125
2019
Q1 		$9.84M Buy
+124,500
New +$8.03M 0.39% 93

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's IMDX Position: Q2 2020 in Review

Emerald Mutual Fund Advisers Trust sold out of Insight Molecular Diagnostics (IMDX) in Q2 2020, closing a stake of 101,795 shares — an estimated $4.99M sold.

Emerald Mutual Fund Advisers Trust first reported a position in IMDX in Q1 2019 and held it in 5 quarters. The position peaked at $9.84M in Q1 2019. 66 funds tracked by Wall St. Rank hold IMDX as of Q2 2020.

  • Emerald Mutual Fund Advisers Trust reported no remaining Insight Molecular Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 101,795 Insight Molecular Diagnostics shares in Q2 2020, an estimated $4.99M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 5 quarters.
  • Emerald Mutual Fund Advisers Trust's Insight Molecular Diagnostics position peaked at $9.84M in Q1 2019.
  • 66 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2020.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2020, filed 28 Jul 2020.